Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoid plus other anti‐emetic agent changes withdrawal due to adverse event ( compared with other anti‐emetic monotherapy (very low certainty).
1 finding from 1 review
Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting
Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal due to lack of efficacy ( compared with other anti‐emetic monotherapy (low certainty).
1 finding from 1 review
Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher absence of vomiting ( compared with placebo (low certainty).
1 finding from 1 review
Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids probably leads to higher absence of nausea and vomiting ( compared with placebo (moderate certainty).
1 finding from 1 review
Participant preference · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher participant preference ( compared with placebo (low certainty).
1 finding from 1 review
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal any reason ( compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal due to adverse event ( compared with placebo (very low certainty).
1 finding from 1 review
Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of vomiting ( compared with other anti‐emetic agent (moderate certainty).
1 finding from 1 review
Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Number of participants with at least 1 bleeding episode · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
Therapeutic or non‐prophylactic platelet transfusion showed no clear difference in number of participants with severe or life‐threatening bleeding up… compared with prophylactic platelet transfusion (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Quality of life ‐ not reported · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Overall mortality · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in overall mortality compared with antibiotics alone (low certainty).
1 finding from 1 review
Infection‐related mortality · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics showed no clear difference in infection‐related mortality compared with antibiotics alone (low certainty).
1 finding from 1 review
People hospitalized for > 10 days · people with chemotherapy‐induced febrile neutropenia
Benefits and harms of CSF plus antibiotics may leads to lower people hospitalized for > 10 days compared with antibiotics alone (low certainty).
1 finding from 1 review